Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.49
+0.31 (5.98%)
At close: Sep 26, 2025, 4:00 PM EDT
5.45
-0.04 (-0.73%)
After-hours: Sep 26, 2025, 7:33 PM EDT
Vir Biotechnology Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Vir Biotechnology stock ranges from a low of $12 to a high of $110. The average analyst price target of $25.73 forecasts a 368.67% increase in the stock price over the next year.
Price Target: $25.73 (+368.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vir Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 5 |
| Buy | 3 | 3 | 3 | 4 | 4 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 9 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +173.22% | Sep 15, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $12 | Buy | Initiates | $12 | +118.58% | Sep 3, 2025 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $12 → $14 | Hold → Strong Buy | Upgrades | $12 → $14 | +155.01% | Aug 27, 2025 |
| Raymond James | Raymond James | Buy Initiates $12 | Buy | Initiates | $12 | +118.58% | Jul 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +155.01% | May 22, 2025 |
Financial Forecast
Revenue This Year
11.62M
from 74.21M
Decreased by -84.34%
Revenue Next Year
12.91M
from 11.62M
Increased by 11.08%
EPS This Year
-3.32
from -3.83
EPS Next Year
-2.86
from -3.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.9M | 31.1M | |||
| Avg | 11.6M | 12.9M | |||
| Low | 4.6M | 2.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -47.6% | 167.9% | |||
| Avg | -84.3% | 11.1% | |||
| Low | -93.8% | -74.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.01 | -2.42 | |||
| Avg | -3.32 | -2.86 | |||
| Low | -3.76 | -3.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.